A Singapore press holdings portal

YourHealth

Saturday, Jul 26, 2014

YourHealth

Bayer says Nexavar fails in breast cancer study

Reuters | Saturday, Jul 26, 2014

FRANKFURT - German drugmaker Bayer said a Phase III trial of cancer drug Nexavar in patients with advanced breast cancer did not meet its primary endpoint of delaying the progression of the disease.

The study, called Resilience, evaluated Nexavar in combination with chemotherapeutic agent capecitabine, in women with HER2-negative breast cancer.

Oral drug Nexavar, which Bayer is developing jointly with Amgen, is approved for use against certain types of liver, kidney and thyroid cancer.

Study details are expected to be presented at an upcoming scientific conference.

 

No comments yet.
Be the first to post comment.